Immunomodulator Therapy in Inflammatory Bowel Disease

Area of Science:

• Gastroenterology
• Immunosuppressive Therapy
• Inflammatory Bowel Disease

Background:

• Azathioprine and 6-mercaptopurine are established treatments for inflammatory bowel disease (IBD).
• Methotrexate and cyclosporine serve as alternative therapies for specific IBD patient populations.
• Long-term safety data for purine analogues in IBD are available.

Purpose of the Study:

• To review the efficacy and safety of immunosuppressive agents in Crohn's disease and ulcerative colitis.
• To evaluate alternative therapies for patients unresponsive to standard treatments.
• To discuss the role of adjunctive therapies and current recommendations for monitoring.

Main Methods:

• Review of existing literature on azathioprine, 6-mercaptopurine, methotrexate, and cyclosporine in IBD.
• Analysis of data regarding induction, maintenance, fistula closure, and steroid sparing.
• Evaluation of safety profiles, including malignancy risk and monitoring guidelines.

Main Results:

• Azathioprine and 6-mercaptopurine demonstrate efficacy in Crohn's disease and ulcerative colitis, including steroid-sparing effects and remission maintenance.
• Methotrexate is an effective alternative for Crohn's disease patients intolerant to azathioprine or 6-mercaptopurine.
• Intravenous cyclosporine shows short-term efficacy in severe ulcerative colitis, with combination therapy achieving high long-term remission rates.

Conclusions:

• Azathioprine and 6-mercaptopurine are valuable for managing IBD, with a favorable long-term safety profile.
• Methotrexate and cyclosporine provide important therapeutic options for specific IBD scenarios.
• Current evidence does not support routine genetic or metabolite testing to guide thiopurine dosing.